✦ LIBER ✦

Efficacy and tolerability of a new controlled-release formulation of metoprolol: A comparison with conventional metoprolol tablets in mild to moderate hypertension

✍ Scribed by J. J. R. Houtzagers; J. G. Smilde; G. Creytens; G. Westergren

Publisher: Springer
Year: 1988
Tongue: English
Weight: 676 KB
Volume: 33
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00578411

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The antianginal efficacy and tolerabilit

The antianginal efficacy and tolerability of controlled-release metoprolol once daily: A comparison with conventional metoprolol tablets twice daily

✍ K. Egstrup; T. Gundersen; R. Härkönen; E. Karlsson; B. Lundgren 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 657 KB

Pharmacokinetic and pharmacodynamic prop

Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets

✍ A. Sandberg; I. Blomqvist; U. E. Jonsson; P. Lundborg 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 635 KB

Effect of controlled-release metoprolol

Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: A comparison with conventional tablets

✍ L. Rydén; B. E. Kristensson; G. Westergren 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 555 KB

Pharmacokinetic and pharmacodynamic comp

Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation

✍ B. Oosterhuis; J. H. G. Jonkman; F. A. Kerkhof 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 480 KB

A double-blind comparison of once-daily

A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension

✍ Ming-Fong Chen; Chi-Yu Yang; Wen-Jone Chen; Chii-Ming Lee; Chau-Chung Wu; Chiau- 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 537 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre